EORTC Phase II chemotherapy studies in prostate cancer.
D004341:Drug Evaluation; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D008937:Mitomycins; D016685:Mitomycin; D014747:Vinblastine; D014751:Vindesine